BCHT(SH:688276) Ge Long Hui A P P·2025-11-12 07:57Core Viewpoint - The approval of the clinical trial for the adolescent and adult combined vaccine by the National Medical Products Administration represents a significant advancement for the company in expanding its vaccine development pipeline and product offerings [1] Group 1: Vaccine Approval - The company has received the clinical trial approval notice for the acellular combined vaccine (DTPa) for adolescents and adults [1] - This vaccine aims to simultaneously prevent whooping cough, diphtheria, and tetanus in individuals aged 10 years and older [1] Group 2: Market Impact - Successful completion of the clinical trials and subsequent market approval will enhance the company's vaccine research and development pipeline [1] - The new vaccine will diversify the company's combined vaccine product matrix, optimizing its product structure and supporting comprehensive business development [1] - This development is expected to provide higher quality vaccination options for the public and create new growth points for the company's performance [1]